Open AccessPrevalence and Predictors of Highly Active Antiretroviral Therapy Use in Patients With HIV Infection in the United States
Author(s) -
Cunningham We,
Markson Le,
Andersen Rm,
Crystal Sh,
Fleishman Ja,
Carol E. Golin,
Allen L. Gifford,
Liu Hh,
Nakazono Tt,
Sally C. Morton,
Bozzette Sa,
Shapiro Mf,
Wenger Nk
Publication year - 2000
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00042560-200010010-00005
Subject(s) - medicine , socioeconomic status , logistic regression , demography , population , medicaid , cohort , prospective cohort study , cohort study , sida , human immunodeficiency virus (hiv) , pediatrics , family medicine , viral disease , environmental health , health care , sociology , economics , economic growth
Highly active antiretroviral therapy (HAART) became standard for HIV in 1996. Studies at that time showed that most people infected with HIV had initiated HAART, but that members of minority groups and poor people had lower HAART use. It is not known whether high levels of HAART use have been sustained or whether socioeconomic and racial disparities have diminished over time.